Stockscreener 앱 받기
5.65
3.91%
-0.23
시간 외 거래:
6.01
0.36
+6.37%
Lixte Biotechnology Holdings Inc 주식(LIXT)의 최신 뉴스
Lixte Biotechnology Shares Edge Lower as Stock Consolidates Near SupportEarnings Sentiment - Newser
Number of shareholders of Lixte Biotechnology Holdings, Inc. – GETTEX:8640 - TradingView
Lixte Biotechnology Holdings Inc. (LIXT) Q4 2024 Earnings: Net Loss of $0.27 Per Share as Pipeline Progress ContinuesPre-Earnings Drift - Newser
Lixte Biotechnology (LIXT) Holds Near Support After Slight DeclineTrending Volume Leaders - Newser
Lixte Biotechnology (LIXT) Slides 5.25% as Stock Tests Key Support at $5.32Inside Day Breakout - Newser
Why Is Lixte Biotechnology Holdings, Inc. (LIXT) Stock Down Today? - Meyka
According to a filing submitted to the U.S. Securities and Exchange Commission, Glimpse Group Inc has announced its future strategic direction. - Bitget
Since the beginning of this year, STRC has increasingly become the main driver behind Strategy Company's Bitcoin acquisitions. - Bitget
Report: US Gold Corp Hires Mining Veteran Walker for Venezuela Project - Bitget
Lixte Biotechnology Holdings Inc. has officially submitted its 10-Q quarterly report to the U.S. Securities and Exchange Commission for the period ending Q1 2026. - Bitget
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update - The Manila Times
LIXTE Biotechnology Holdings, Inc. Files Q1 2026 10-Q Report, Highlights Progress in Cancer Treatment Development - Quiver Quantitative
LIXTE BIOTECHNOLOGY HOLDINGS, INC. 1Q 2026: Net loss $1.94M, EPS $(0.18) — 10-Q Summary - TradingView
Lixte (NASDAQ: LIXT) Q1 2026 loss deepens amid going-concern risks - Stock Titan
Inside LIXTE’s push on ovarian cancer and proton therapy - Stock Titan
TradingKey - TradingKey
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
LIXT SEC FilingsLixte Biotechnology Hldgs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lixte Biotechnology Holdings, Inc. (LIXT) Latest Stock News & Headlines - Yahoo Finance
LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment - NewMediaWire
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment - TipRanks
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100 - citybuzz -
LIXT Lixte posts Q4 2024 negative EPS of 27 cents and zero revenue, with shares unchanged today.EBITDA Margin - Cổng thông tin điện tử tỉnh Tây Ninh
LIXT Lixte Biotechnology Holdings Inc. shares gain 6.87 percent on positive investor reaction to Q4 2024 earnings release.Professional Trade Ideas - Xã Thanh Hà
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - The Globe and Mail
Lixte (LIXT) Stock Volume Stability (Bearish Sentiment) 2026-04-20Crowd Entry Signals - Cổng thông tin điện tử tỉnh Lào Cai
LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - NewMediaWire
Why Cardio Diagnostics Holdings (NASDAQ: CDIO) Is ‘One to Watch’ - Financial-News.co.uk
Lixte Biotechnology stock (US53833K1060): Is its PP2A cancer focus strong enough to unlock breakthro - AD HOC NEWS
Lixte Biotechnology Holdings, Inc. Files Form 8-K with SEC Detailing Restricted Share Unit Awards and Company Information (April 2026) - Minichart
Lixte Biotechnology Updates Executive Equity Compensation With RSUs - The Globe and Mail
Lixte Biotechnology Holdings, Inc. (LIXTW) - Minichart
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors - Investing.com India
LIXTE Biotechnology’s LB-100 Represents Novel Approach to Enhancing Cancer Therapies - citybuzz -
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors By Investing.com - Investing.com South Africa
Lixte Biotechnology (LIXT) CEO cancels 350K options for shares - Stock Titan
Lixte (LIXT) CFO cancels 50K options, receives 50K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options and receives 25K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options, receives 25K RSUs vesting immediately - Stock Titan
Lixte (LIXT) cancels insider stock options and grants fully vested RSUs - Stock Titan
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built - The Globe and Mail
"NextEpochMarket company news.lhl"Results on X | Live Posts & Updates - x.com
LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - USA Today
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - NewMediaWire
Options Flow: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity Warrant2026 Macro Impact & AI Forecast Swing Trade Picks - baoquankhu1.vn
0.98%
0.12%
자본화:
|
볼륨(24시간):